New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 27, 2013
09:21 EDTNOK, JCP, BWS, MOV, CPRX, SAFM, HITK, TIF, LDK, DSW, AKRXOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Tiffany & Co. (TIF), up 1%... Movado Group (MOV), up 5%... Brown Shoe Company (BWS), up 4.4%... DSW (DSW), up 2%... Sanderson Farms (SAFM), up 2.3%... ALSO HIGHER: Catalyst Pharmaceutical (CPRX), up 64% after receiving breakthrough therapy designation by FDA... Akorn (AKRX), up 7% after agreeing to buy Hi-Tech Pharmacal (HITK). Hi-Tech also up 22%... DOWN AFTER EARNINGS: LDK Solar (LDK), down 12%. LOWER: J.C. Penney (JCP), down 2% after Bill Ackman's Pershing Square sells 39M shares... Acura Pharmaceuticals (ACUR), down 23.5% after results for a clinical trial's primary endpoint were not statistically significant... Nokia (NOK), down 3.6% after Deutsche Bank says company possibly facing another restructuring.
News For TIF;MOV;AKRX;HITK;BWS;DSW;SAFM;JCP;LDK;CPRX;NOK From The Last 14 Days
Check below for free stories on TIF;MOV;AKRX;HITK;BWS;DSW;SAFM;JCP;LDK;CPRX;NOK the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
April 17, 2014
16:18 EDTHITK, AKRXActavis to purchase four marketed products from Akorn and Hi-Tech Pharmacal
Actavis (ACT) announced that it has entered into agreements with Akorn (Akrx) and Hi-Tech Pharmacal (HITK) to purchase four currently marketed products and one product under development for cash consideration. The closing of the purchase agreements are contingent upon the consummation of Akorn's acquisition of Hi-Tech. Financial terms of the agreements were not disclosed. The agreements include three products marketed under Abbreviated New Drug Applications and one product marketed under a New Drug Application: Lidocaine/Prilocaine Topical Cream. The agreements also include one product under development.
09:21 EDTHITK, AKRXAkorn completes acquisition of Hi-Tech Pharmacal for $640M in cash
Akorn (AKRX) announced that it has completed its previously announced acquisition of Hi-Tech Pharmacal (HITK) for $640M in cash. The combination of Akorn and Hi-Tech will transform the company into a larger, more diversified generic player.
07:43 EDTNOKNokia advises discontinued use of AC-300 charger for Lumia 2520 tablet in Europe
Nokia announced a product advisory for the European and UK variant of the AC-300 charger, which is used exclusively with the Lumia 2520 tablet. Consumers in Austria, Denmark, Finland, Germany, Russia, Switzerland and UK are strongly advised to suspend use of the charger until further notice. Also, consumers who purchased the Lumia 2520 travel charger accessory in Austria, Denmark, Finland, Germany, Russia, Switzerland, UK and the U.S. are strongly advised to suspend use of the travel charger accessory. In total, approximately 30,000 chargers are impacted by this advisory. This includes approximately 600 travel charger accessories sold in the U.S.
07:08 EDTDSWDSW appoints Mary Meixelsperger as CFO effective May 1
Meixelsperger replaces Douglas Probst, who is retiring from DSW on the same day. Meixelsperger joins DSW from Shopko Stores, a regional discount store chain, where she held the roles of Chief Financial Officer, Controller and Treasurer.
April 16, 2014
06:22 EDTNOKNokia increases orders for on-cell touch panels, DigiTimes reports
Subscribe for More Information
April 15, 2014
17:55 EDTHITK, AKRXRepligen to replace Hi-Tech Pharmacal in S&P 600 as of 4/17
Subscribe for More Information
12:15 EDTNOKStocks with call strike movement; MU NOK
Subscribe for More Information
10:00 EDTTIFOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:47 EDTTIFTiffany China business poised to continue growth, says Sterne Agee
Subscribe for More Information
08:19 EDTTIFTiffany upgraded to Overweight from Equal Weight at Stephens
Subscribe for More Information
06:33 EDTDSWDSW acquires approximately 44% interest in Town of shoes in Canada
DSW Inc. and Town Shoes announced that they have entered into a definitive agreement whereby DSW Inc. will purchase for cash approximately 44% interest in Town Shoes for approximately $62M. The transaction has been approved by each company's board and is expected to close in May. DSW Inc. is purchasing its initial 44% stake from AIMCo and may acquire additional shares from certain other minority shareholders as part of its initial investment. Additionally, DSW Inc. will have the right to purchase the balance of Town Shoes from the remaining shareholders, including Callisto Capital, after four years at a pre-determined EBITDA multiple. Callisto, on behalf of itself and the remaining shareholders, has the right to put the balance of the company to DSW Inc. after three years at a pre-determined EBITDA multiple. DSW Inc.'s initial stake provides 50% voting control and board representation, both of which are equal to that of Callisto. The transaction, which the company anticipates to record under the equity method, is expected to be slightly accretive to earnings in FY14, excluding one-time transaction expenses.
06:30 EDTDSWDSW acquires approximately 44% interest in Town of shoes in Canada
April 14, 2014
19:01 EDTAKRX, HITKAkorn gets FTC clearance for Hi-Tech Pharmacal deal
Akorn (AKRX) announced that the U.S. FTC has voted to approve Akornís acquisition of Hi-Tech Pharmacal (HITK). The unanimous vote in support of the transactions follows Akornís agreement to a proposed consent order requiring divestiture of certain products as a condition to obtaining FTC approval. The parties have now obtained all regulatory approvals required to consummate the acquisition, and intend to close by the end of this week.
10:02 EDTCPRXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:14 EDTCPRXCatalyst Pharmaceutical initiated with an Overweight at Piper Jaffray
Target $4.
April 11, 2014
14:26 EDTJCPCBL & Associates expects more J.C. Penney closures
Subscribe for More Information
08:12 EDTTIFTiffany announces General Counsel to retire
Subscribe for More Information
April 10, 2014
07:31 EDTBWSBrown Shoe made material progress in it restructuring, says Brean Capital
Brean Capital said Brown Shoe made material progress in its restructuring to improve operating performance. The firm cited lower debt, continued store and channel optimization, and significant free cash flow. Shares are Buy rated with a $36 price target.
April 9, 2014
12:07 EDTSAFMU.S. red meat, poultry production forecast lowered
Subscribe for More Information
09:20 EDTTIFBofA/Merrill's retail analysts hold an analyst/industry conference call
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use